User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks

Primary tabs

Elens, Laure [UCL] Bouamar, Rachida Shuker, Nauras Hesselink, Dennis A. Van Gelder, Teun Van Schaik, Ron H. N.

Pharmacogenetics has generated many expectations for its potential to individualize therapy proactively and improve medical care. However, despite the huge amount of reported genetic associations with either pharmacokinetics or pharmacodynamics of drugs, the translation into patient care is still slow. In fact, strong evidence for a substantial clinical benefit of pharmacogenetic testing is still limited, with a few exceptions. In kidney transplantation, established pharmacogenetic discoveries are being investigated for application in the clinic to improve efficacy and to limit toxicity associated with the use of immunosuppressive drugs, especially the frequently used calcineurin inhibitors (CNIs) tacrolimus and ciclosporin. The purpose of the present review is to picture the current status of CNI pharmacogenetics and to discuss the most promising leads that have been followed so far. © 2013 The British Pharmacological Society.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "British Journal of Clinical Pharmacology" - Vol. 77, no. 4, p. 715-728 (2014)
Peer reviewed yes
Publisher Wiley-Blackwell ((United Kingdom) Oxford)
issn 0306-5251
e-issn 1365-2125
Publication status Publié
Affiliation UCL - SSS/LDRI - Louvain Drug Research Institute
Links
  1. Hariharan Sundaram, Johnson Christopher P., Bresnahan Barbara A., Taranto Sarah E., McIntosh Matthew J., Stablein Donald, Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996, 10.1056/nejm200003023420901
  2. Dunn Christopher J., Wagstaff Antona J., Perry Caroline M., Plosker Greg L., Goa Karen L., Cyclosporin : An Updated Review of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral??)* in Organ Transplantation, 10.2165/00003495-200161130-00006
  3. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation : , 10.2165/00003088-200443100-00001
  4. Bouamar R., Shuker N., Hesselink D. A., Weimar W., Ekberg H., Kaplan B., Bernasconi C., van Gelder T., Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials† : Tacrolimus Concentrations and Acute Rejection, 10.1111/ajt.12191
  5. Pascual Manuel, Theruvath Tom, Kawai Tatsuo, Tolkoff-Rubin Nina, Cosimi A. Benedict, Strategies to Improve Long-Term Outcomes after Renal Transplantation, 10.1056/nejmra011295
  6. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, Pharmacogenetics in Kidney Transplantation : Recent Updates and Potential Clinical Applications, 10.1007/s40291-012-0012-5
  7. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II : , 10.2165/11317550-000000000-00000
  8. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I : , 10.2165/11317350-000000000-00000
  9. Metalidis, Minerva Urol Nefrol, 63, 1 (2011)
  10. Picard Nicolas, Marquet Pierre, The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation, 10.1517/17425255.2011.570260
  11. Sprangers Ben, Kuypers Dirk R., Vanrenterghem Yves, Immunosuppression: Does One Regimen Fit All? : , 10.1097/tp.0b013e31822094d1
  12. Kronbach Thomas, Fischer Volker, Meyer Urs A, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, 10.1038/clpt.1988.87
  13. Dai Yang, Iwanaga Kazunori, Lin Yvonne S., Hebert Mary F., Davis Connie L., Huang Weili, Kharasch Evan D., Thummel Kenneth E., In vitro metabolism of cyclosporine A by human kidney CYP3A5, 10.1016/j.bcp.2004.07.012
  14. Elens Laure, van Gelder Teun, Hesselink Dennis A, Haufroid Vincent, van Schaik Ron HN, CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy, 10.2217/pgs.12.187
  15. Min David I., Ellingrod Vicki L., Association of the CYP3A4*1B 5´-Flanking Region Polymorphism With Cyclosporine Pharmacokinetics in Healthy Subjects : , 10.1097/00007691-200306000-00010
  16. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R., Increased transcriptional activity of theCYP3A4*1B promoter variant, 10.1002/em.10199
  17. Singh Ranjana, Srivastava Aneesh, Kapoor Rakesh, K. Sharma Raj, D. Mittal Rama, Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India, 10.1007/s00210-009-0415-y
  18. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  19. Rivory L. P., Qin H., Clarke S. J., Eris J., Duggin G., Ray E., Trent R. J., Bishop J. F., Frequency of cytochrome P 450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance, 10.1007/s002280000166
  20. Ahsen, Clin Chem, 47, 1048 (2001)
  21. HESSELINK D, VANGELDER T, VANSCHAIK R, BALK A, VANDERHEIDEN I, VANDAM T, VANDERWERF M, WEIMAR W, MATHOT R, Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes, 10.1016/j.clpt.2004.08.022
  22. Pączek Leszek, Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients, 10.12659/aot.883456
  23. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, 10.1038/86882
  24. Hu Y.-F., Tu J.-H., Tan Z.-R., Liu Z.-Q., Zhou G., He J., Wang D., Zhou H.-H., Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects, 10.1080/00498250601149206
  25. Meng Xiang-guang, Guo Cheng-xian, Feng Guo-qing, Zhao Ying-chun, Zhou Bo-ting, Han Jian-le, Chen Xin, Shi Yong, Shi Hong-yao, Yin Ji-ye, Peng Xiang-dong, Pei Qi, Zhang Wei, Wang Guo, He Meng, Liu Min, Yang Jing-ke, Zhou Hong-hao, Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China, 10.1038/aps.2012.136
  26. Qiu Xiao-yan, Jiao Zheng, Zhang Ming, Zhong Long-jin, Liang Hui-qi, Ma Chun-lai, Zhang Liang, Zhong Ming-kang, Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients, 10.1007/s00228-008-0520-8
  27. Li Dan-ying, Teng Rui-chen, Zhu Huai-jun, Fang Yun, CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients, 10.5414/cp201836
  28. Zheng Songmao, Tasnif Yasar, Hebert Mary F., Davis Connie L., Shitara Yoshihisa, Calamia Justina C., Lin Yvonne S., Shen Danny D., Thummel Kenneth E., CYP3A5 Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition : , 10.1097/tp.0b013e31827e6ad9
  29. Haehner, Mol Pharmacol, 50, 52 (1996)
  30. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  31. Anglicheau D, CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, 10.1016/j.clpt.2004.01.009
  32. Kreutz Reinhold, Z??rcher Heiko, Kain Silke, Martus Peter, Offermann Gerd, Beige Joachim, The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients : , 10.1097/00008571-200410000-00004
  33. Zhao Y., Song M., Guan D., Bi S., Meng J., Li Q., Wang W., Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus, 10.1016/j.transproceed.2005.01.077
  34. Tang Hui-Lin, Ma Lu-Lin, Xie Hong-Guang, Zhang Ting, Hu Yong-Fang, Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis : , 10.1097/fpc.0b013e32833ccd56
  35. Fukushima-Uesaka Hiromi, Saito Yoshiro, Watanabe Hidemi, Shiseki Kisho, Saeki Mayumi, Nakamura Takahiro, Kurose Kouichi, Sai Kimie, Komamura Kazuo, Ueno Kazuyuki, Kamakura Shiro, Kitakaze Masafumi, Hanai Sotaro, Nakajima Toshiharu, Matsumoto Kenji, Saito Hirohisa, Goto Yu-ichi, Kimura Hideo, Katoh Masaaki, Sugai Kenji, Minami Narihiro, Shirao Kuniaki, Tamura Tomohide, Yamamoto Noboru, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Kitamura Yutaka, Kamatani Naoyuki, Ozawa Shogo, Sawada Jun-ichi, Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population, 10.1002/humu.9210
  36. Zeng Yong, He Yi-jing, He Fu-yuan, Fan Lan, Zhou Hong-hao, Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects, 10.1038/aps.2009.27
  37. Elens, Pharmacogenet Genomics, 22, 373 (2012)
  38. Elens Laure, Nieuweboer Annemieke, Clarke Stephen J, Charles Kellie A, de Graan Anne-Joy, Haufroid Vincent, Mathijssen Ron HJ, van Schaik Ron HN, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin, 10.2217/pgs.12.202
  39. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
  40. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  41. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  42. Metalidis Christoph, Lerut Evelyne, Naesens Maarten, Kuypers Dirk R.J., Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity : , 10.1097/tp.0b013e3182177502
  43. Hauser I. A., ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation, 10.1681/asn.2004100882
  44. Kato Ryuji, Nishide Mami, Kozu Chihiro, Iwamoto Asuka, Urashima Kazuya, Suzuki Kaoru, Ijiri Yoshio, Hayashi Tetsuya, Tanaka Kazuhiko, Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?, 10.1007/s00228-009-0740-6
  45. Shuker Nauras, Bouamar Rachida, Weimar Willem, van Schaik Ron.H.N., van Gelder Teun, Hesselink Dennis A., ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation, 10.1016/j.cca.2011.09.040
  46. Naesens M., Lerut E., de Jonge H., Van Damme B., Vanrenterghem Y., Kuypers D. R. J., Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts, 10.1681/asn.2009020192
  47. Joy Melanie S., Nickeleit Volker, Hogan Susan L., Thompson Bawana D., Finn William F., Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P-glycoprotein, 10.1592/phco.2005.25.6.779
  48. Kimchi-Sarfaty C., Oh J. M., Kim I.-W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M., A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, 10.1126/science.1135308
  49. Wang Danxin, Johnson Andrew D., Papp Audrey C., Kroetz Deanna L., Sadée Wolfgang, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability : , 10.1097/01.fpc.0000178311.02878.83
  50. Woillard J-B, Rerolle J-P, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P, Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, 10.1038/clpt.2010.62
  51. Moore J., McKnight A. J., Dohler B., Simmonds M. J., Courtney A. E., Brand O. J., Briggs D., Ball S., Cockwell P., Patterson C. C., Maxwell A. P., Gough S. C. L., Opelz G., Borrows R., Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, 10.1681/asn.2012030260
  52. Huls M., Kramers C., Levtchenko E.N., Wilmer M.J.G., Dijkman H.B.P.M., Kluijtmans L.A.J., van der Hoorn J.W.A., Russel F.G.M., Masereeuw R., P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury, 10.1038/sj.ki.5002522
  53. Huls Miriam, Schoeber Joost P. H., Verfaillie Catherine M., Luttun Aernout, Ulloa-Montoya Fernando, Menke Aswin L., Van Bolderen Lars R., Woestenenk Rob M., Merkx Gerard F. M., Wetzels Jack F. M., Russel Frans G. M., Masereeuw Rosalinde, Deficiency of Either P-Glycoprotein or Breast Cancer Resistance Protein Protect against Acute Kidney Injury, 10.3727/096368910x504478
  54. Bandur Stepan, Petrasek Jan, Hribova Petra, Novotna Eva, Brabcova Irena, Viklicky Ondrej, Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients : , 10.1097/tp.0b013e318187c4d1
  55. Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin B., Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients : , 10.1097/fpc.0b013e3282f7046f
  56. Grinyó Josep, Vanrenterghem Yves, Nashan Björn, Vincenti Flavio, Ekberg Henrik, Lindpaintner Klaus, Rashford Michelle, Nasmyth-Miller Clare, Voulgari Athina, Spleiss Olivia, Truman Matthew, Essioux Laurent, Association of four DNA polymorphisms with acute rejection after kidney transplantation, 10.1111/j.1432-2277.2008.00679.x
  57. Hubbard Paul A., Shen Anna L., Paschke Rosemary, Kasper Charles B., Kim Jung-Ja P., NADPH-Cytochrome P450 Oxidoreductase : STRUCTURAL BASIS FOR HYDRIDE AND ELECTRON TRANSFER, 10.1074/jbc.m101731200
  58. Huang N., Agrawal V., Giacomini K. M., Miller W. L., Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, 10.1073/pnas.0711621105
  59. Elens L Hesselink DA Bouamar R Budde K de Fijter JW De Meyer M Mourad M Kuypers DR Haufroid V van Gelder T van Schaik RH Impact of POR*28 on the pharmacokinetics of Tacrolimus and Cyclosporine a in renal transplant patients
  60. Kamdem L. K., Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus, 10.1373/clinchem.2005.050047
  61. Elens Laure, Capron Arnaud, Kerckhove Valérie Van, Lerut Jan, Mourad Michel, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation : , 10.1097/fpc.0b013e3282e9a533
  62. Goto Maki, Masuda Satohiro, Kiuchi Tetsuya, Ogura Yasuhiro, Oike Fumitaka, Okuda Masahiro, Tanaka Koichi, Inui Ken-ichi, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation : , 10.1097/01.fpc.0000114747.08559.49
  63. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D. C., Malaise J., Lison D., Mourad M., CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, 10.1111/j.1600-6143.2006.01518.x
  64. Hesselink Dennis A., van Schaik Ron H.N., van Agteren Madelon, de Fijter Johannes W., Hartmann Anders, Zeier Martin, Budde Klemens, Kuypers Dirk R.J., Pisarski Przemyslav, Meur Yann Le, Mamelok Richard D., van Gelder Teun, CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients : , 10.1097/fpc.0b013e3282f75f88
  65. Kuypers D R J, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y, CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients, 10.1038/sj.clpt.6100216
  66. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/01.tp.0000151766.73249.12
  67. Thervet Eric, Anglicheau Dany, King Barry, Schlageter Marie-H??l??ne, Cassinat Bruno, Beaune Philippe, Legendre Christophe, Daly Ann K., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 : , 10.1097/01.tp.0000090753.99170.89
  68. Tsuchiya Norihiko, Satoh Shigeru, Tada Hitoshi, Li Zhenhua, Ohyama Chikara, Sato Kazunari, Suzuki Toshio, Habuchi Tomonori, Kato Tetsuro, Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients : , 10.1097/01.tp.0000137789.58694.b4
  69. van Gelder T, Hesselink D A, Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?, 10.1038/clpt.2010.42
  70. Zheng HongXia, Webber Steven, Zeevi Adriana, Schuetz Erin, Zhang Jiong, Bowman Pamela, Boyle Gerard, Law Yuk, Miller Susan, Lamba Jatinder, Burckart Gilbert J., Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms, 10.1034/j.1600-6143.2003.00077.x
  71. Zheng HongXia, Zeevi Adriana, Schuetz Erin, Lamba Jatinder, McCurry Kenneth, Griffith Bartley P., Webber Steven, Ristich Julianne, Dauber James, Iacono Aldo, Grgurich Wayne, Zaldonis Diana, McDade Kevin, Zhang Jiong, Burckart Gilbert J., Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism, 10.1177/0091270003262108
  72. MacPhee Iain A. M., Fredericks Salim, Tai Tracy, Syrris Petros, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, 10.1111/j.1600-6143.2004.00435.x
  73. Undre N. A., Pharmacokinetics of tacrolimus-based combination therapies, 10.1093/ndt/gfg1029
  74. Undre N.A, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales J.M, Andrés A, Schäfer A, Stevenson P, Low systemic exposure to tacrolimus correlates with acute rejection, 10.1016/s0041-1345(98)01633-9
  75. Chen J.S., Li L.S., Cheng D.R., Ji S.M., Sun Q.Q., Cheng Z., Wen J.Q., Sha G.Z., Liu Z.H., Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus, 10.1016/j.transproceed.2009.01.097
  76. Tang Hui-Lin, Xie Hong-Guang, Yao Yao, Hu Yong-Fang, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers : , 10.1097/fpc.0b013e32834a48ca
  77. Birdwell Kelly A., Grady Ben, Choi Leena, Xu Hua, Bian Aihua, Denny Josh C., Jiang Min, Vranic Gayle, Basford Melissa, Cowan James D., Richardson Danielle M., Robinson Melanie P., Ikizler Talat Alp, Ritchie Marylyn D., Stein Charles Michael, Haas David W., The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients : , 10.1097/fpc.0b013e32834e1641
  78. Hesselink Dennis A, Bouamar Rachida, van Gelder Teun, The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity : , 10.1097/ftd.0b013e3181e44244
  79. MacPhee Iain A.M., Pharmacogenetic biomarkers: cytochrome P450 3A5, 10.1016/j.cca.2011.10.013
  80. Thervet, Clin Pharmacol Ther, 87, 721 (2010)
  81. Passey Chaitali, Birnbaum Angela K., Brundage Richard C., Oetting William S., Israni Ajay K., Jacobson Pamala A., Dosing equation for tacrolimus using genetic variants and clinical factors : Tacrolimus dosing equation, 10.1111/j.1365-2125.2011.04039.x
  82. Boughton Oliver, Borgulya Gabor, Cecconi Maurizio, Fredericks Salim, Moreton-Clack Michelle, MacPhee Iain A. M., A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients : Test of tacrolimus pharmacogenetic dosing algorithm, 10.1111/bcp.12076
  83. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, TheCYP3A4*22allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations : Letter to the Editors, 10.1111/bcp.12038
  84. Elens, Ther Drug Monit, 35, 608 (2013)
  85. Gijsen Violette MGJ, van Schaik Ron HN, Elens Laure, Soldin Offie P, Soldin Steven J, Koren Gideon, de Wildt Saskia N, CYP3A4*22andCYP3Acombined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients, 10.2217/pgs.13.80
  86. Capron Arnaud, Lerut Jan, Latinne Dominique, Rahier Jacques, Haufroid Vincent, Wallemacq Pierre, Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study : PBMCs tacrolimus levels and graft rejection, 10.1111/j.1432-2277.2011.01365.x
  87. Capron Arnaud, Mourad Michel, De Meyer Martine, De Pauw Luc, Eddour Djamila Chaib, Latinne Dominique, Elens Laure, Haufroid Vincent, Wallemacq Pierre, CYP3A5andABCB1polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, 10.2217/pgs.10.43
  88. De Meyer Martine, Haufroid Vincent, Elens Laure, Fusaro Fabio, Patrono Damiano, De Pauw Luc, Kanaan Nada, Goffin Eric, Mourad Michel, Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation, 10.1016/j.jss.2012.06.070
  89. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77
  90. Op den Buijsch Robert A.M., Christiaans Maarten H.L., Stolk Leo M.L., de Vries Johan E., Cheung Chi Yuen, Undre Nas A., van Hooff Johannes P., van Dieijen-Visser Marja P., Bekers Otto, Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms, 10.1111/j.1472-8206.2007.00504.x
  91. Tirelli, Med Sci Monit, 14, CR251 (2008)
  92. Zhang Xin, Liu Zhi-hong, Zheng Jing-min, Chen Zhao-hong, Tang Zheng, Chen Jin-song, Li Lei-shi, Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation, 10.1111/j.1399-0012.2005.00370.x
  93. Loh P.T., Lou H.X., Zhao Y., Chin Y.M., Vathsala A., Significant Impact of Gene Polymorphisms on Tacrolimus But Not Cyclosporine Dosing in Asian Renal Transplant Recipients, 10.1016/j.transproceed.2008.04.010
  94. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I, CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients, 10.1038/sj.clpt.6100039
  95. Satoh Shigeru, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Miura Masatomo, Inoue Kazuyuki, Numakura Kazuyuki, Tsuchiya Norihiko, Tada Hitoshi, Suzuki Toshio, Habuchi Tomonori, Lack of tacrolimus circadian pharmacokinetics andCYP3A5pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients, 10.1111/j.1365-2125.2008.03188.x
  96. Roy Jean Nicholas, Barama Azemi, Poirier Charles, Vinet Bernard, Roger Michel, Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients : , 10.1097/01.fpc.0000220571.20961.dd
  97. Mourad Michel, Wallemacq Pierre, De Meyer Martine, Brandt Dimitri, Van Kerkhove Valérie, Malaise Jacques, Chaïb Eddour Djamila, Lison Dominique, Haufroid Vincent, The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function, 10.1515/cclm.2006.229
  98. Fredericks Salim, Moreton Michelle, Reboux Sandrine, Carter Nicholas D., Goldberg Lawrence, Holt David W., MacPhee Iain A. M., Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements : , 10.1097/01.tp.0000234942.78716.c0
  99. Tada H., Tsuchiya N., Satoh S., Kagaya H., Li Z., Sato K., Miura M., Suzuki T., Kato T., Habuchi T., Impact of CYP3A5 and MDR1(ABCB1) C3435T Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients, 10.1016/j.transproceed.2005.02.073
  100. Mourad Michel, Mourad Georges, Wallemacq Pierre, Garrigue Val??rie, Van Bellingen Christophe, Van Kerckhove Val??rie, De Meyer Martine, Malaise Jacques, Eddour Djamila Chaib, Lison Dominique, Squifflet Jean Paul, Haufroid Vincent, Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids : , 10.1097/01.tp.0000174131.47469.d2
  101. Cheung Chi Yuen, Op den Buijsch Robert AM, Ming Wong Kim, Wong Chan Hoi, Foon Chau Ka, Sang Li Chun, Tai Leung Kay, Hoi Kwan Tze, de Vrie Johan E, Wijnen Petal AHM, van Dieijen-Visser Marja P, Bekers Otto, Influence of different allelic variants of theCYP3AandABCB1genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients, 10.2217/14622416.7.4.563
Bibliographic reference Elens, Laure ; Bouamar, Rachida ; Shuker, Nauras ; Hesselink, Dennis A. ; Van Gelder, Teun ; et. al. Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks. In: British Journal of Clinical Pharmacology, Vol. 77, no. 4, p. 715-728 (2014)
Permanent URL http://hdl.handle.net/2078.1/159832